Acasti Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Acasti Pharma generated cash of -$12,333,000, which is more than the previous year. Cash used in financing activities reached the amount of $7,359,000 last year. Net change in cash is therefore -$4,870,000.
Cash Flow
| 2010 | -1.90M | 1.90M | 77.40K |
|---|---|---|---|
| 2011 | -1.90M | -2.58M | 4.39M |
| 2012 | -5.64M | -3.00M | 9.94M |
| 2016 | -4.85M | 6.07M | -1.78K |
| 2018 | -9.69M | -318.25K | 8.83M |
| 2020 | -22.94M | 8.13M | 13.17M |
| 2021 | -14.31M | -9.85M | 59.49M |
| 2023 | -15.91M | 13.15M | 304K |
| 2024 | -12.33M | 104K | 7.35M |
ACST Cash Flow Statement (2010 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 27.87M | 30.33M | 14.24M | 16.87M | 7.56M | 967.12K | 324.05K | 422.10K | 312.57K |
Operating activities | |||||||||
Net income | -12.85M | -42.42M | -19.67M | -25.51M | -16.65M | -4.66M | -6.53M | -2.42M | -1.50M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 11K | 124K | 924K | 2.32M | 2.06M | 1.76M | 671.76K | 13.33K | 8.62K |
Stock-based compensation expense | 913K | 1.81M | 1.17M | 1.95M | 719.36K | 227.73K | 1.32M | 108.14K | 0 |
| Deferred income tax benefit | 913K | 1.81M | 1.17M | 1.95M | 719.36K | 227.73K | 1.32M | 108.14K | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 80K | -408 | 58K | 581K | -428.21K | 34.89K | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 64.47K | -602.93K | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 36.93K | 0 | 0 | 0 |
Cash generated by operating activities | -12.33M | -15.91M | -14.31M | -22.94M | -9.69M | -4.85M | -5.64M | -1.90M | -1.90M |
Investing activities | |||||||||
Purchases Of Investments | -6.55M | -5.01M | -9.81M | -1.92M | -20.13K | -8.82M | -7.54M | -2.56M | 0 |
Investments In Property Plant And Equipment | -22K | -17K | -69K | -319K | -352.32K | -271.25K | 0 | -21.57K | -15.35K |
Acquisitions Net | 111K | 5.03M | 9.87M | 2.24M | 0 | -67.57K | 0 | 0 | 0 |
Cash generated by investing activities | 104K | 13.15M | -9.85M | 8.13M | -318.25K | 6.07M | -3.00M | -2.58M | 1.90M |
Financing activities | |||||||||
Common Stock Issued | 7.33M | 304K | 59.33M | 6.98M | 8.53M | 0 | 9.88M | 4.39M | 77.40K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -1.55M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 7.35M | 304K | 59.49M | 13.17M | 8.83M | -1.78K | 9.94M | 4.39M | 77.40K |
Net Change In Cash | -4.87M | -2.46M | 36.70M | -2.63M | -1.19M | 1.26M | 1.27M | -92.67K | 80.17K |
Cash at end of period | 23.00M | 27.87M | 50.94M | 14.24M | 6.36M | 2.23M | 1.59M | 329.43K | 392.75K |
| Data source | Data source | Data source | Data source | Data source | Data source |